500655 Sigma-AldrichRad6 Inhibitor, TZ9 - CAS 1002789-86-7 - Calbiochem
Rad6 Inhibitor, TZ9, CAS 002789-86-7, is a cell-permeable inhibitor of Rad6B-Ub thioester bond formation and subsequent substrate ubiquitination. Directly binds to the catalytic site of Rad6B/HHR6B.
More>> Rad6 Inhibitor, TZ9, CAS 002789-86-7, is a cell-permeable inhibitor of Rad6B-Ub thioester bond formation and subsequent substrate ubiquitination. Directly binds to the catalytic site of Rad6B/HHR6B. Less<<Synonymes: TZ9, TZ-9, TZ 9, HHR6 Inhibitor, 4-Amino-6-(phenylamino)-[1,3,5]triazin-2-yl)methyl-4-nitrobenzoate, (4-Amino-6-(phenylamino)-1,3,5-triazin-2-yl)methyl 4-nitrobenzoate
Produits recommandés
Aperçu
Replacement Information |
---|
Prix & Disponibilité
Référence | Disponibilité | Conditionnement | Qté | Prix | Quantité | |
---|---|---|---|---|---|---|
5006550001 |
|
Flacon en verre | 10 mg |
|
— |
References | |
---|---|
References | Sanders, M.A., et al. 2013. Mol. Cancer Ther. 12, 373. |
Product Information | |
---|---|
CAS number | 1002789-86-7 |
Form | Pale yellow solid |
Hill Formula | C₁₇H₁₄N₆O₄ |
Chemical formula | C₁₇H₁₄N₆O₄ |
Reversible | Y |
Structure formula Image | |
Quality Level | MQ200 |
Biological Information | |
---|---|
Primary Target | Rad6B/HHR6B |
Purity | ≥99% by HPLC |
Physicochemical Information | |
---|---|
Cell permeable | Y |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Référence | GTIN |
5006550001 | 04055977245059 |
Documentation
Rad6 Inhibitor, TZ9 - CAS 1002789-86-7 - Calbiochem FDS
Titre |
---|
Rad6 Inhibitor, TZ9 - CAS 1002789-86-7 - Calbiochem Certificats d'analyse
Titre | Numéro de lot |
---|---|
500655 |
Références bibliographiques
Aperçu de la référence bibliographique |
---|
Sanders, M.A., et al. 2013. Mol. Cancer Ther. 12, 373. |